Achieving Portal Access With Scorpion Post-Approval Study (APASS)

March 7, 2024 updated by: Argon Medical Devices

A Prospective, Multicenter, Randomized Study Evaluating Portal Vein Access Sets During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedures

Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure. The purpose of this study is to evaluate portal vein access sets during the TIPS procedure.

Study Overview

Study Type

Interventional

Enrollment (Actual)

3

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Emory University
    • New York
      • New York, New York, United States, 10032
        • New York Presbyterian - Columbia University Medical Center
        • Contact:
        • Principal Investigator:
          • Venkatesh Krishnasamy, MD
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599
        • University of North Carolina at Chapel Hill
        • Principal Investigator:
          • Clayton Commander, MD
        • Contact:
        • Sub-Investigator:
          • Hyeon Yu, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. ≥ 18 years of age at the time of the TIPS procedure
  2. TIPS procedure initiated for refractory variceal bleeding, refractory ascites and/or hydrothorax
  3. Willing and able to provide written informed consent and HIPAA (Health Insurance Portability and Accountability Act) authorization
  4. Willing and able to comply with the study procedures and follow up schedule

Exclusion Criteria:

  1. Known active malignancy
  2. MELD score ≥ 18 at time of screening
  3. History of polycystic liver disease
  4. Active bleeding from any source
  5. Pulmonary hypertension, heart failure, severe tricuspid valve dysfunction, right to left cardiopulmonary shunt
  6. Chronic, occlusive portal vein thrombosis or complete portal vein thrombosis of the main or target portal vein on prior CT examination
  7. Active or uncontrolled hepatic encephalopathy
  8. Systemic infection/sepsis
  9. Biliary obstruction
  10. Uncorrectable coagulopathy
  11. Any diminutive or partially thrombosed right portal vein
  12. Hepatic vein thrombosis (i.e., no Budd-Chiari syndrome)
  13. Known sensitivity to contrast or serious contrast reaction such as anaphylaxis
  14. Pregnant women or women who are planning to become pregnant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: TIPS with Scorpion Portal Vein Access Kit
Scorpion or Scorpion X access set
Portal Vein Access with Scorpion or Scorpion X set
Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Active Comparator: TIPS with Cook Transjugular Liver Access Set
Ring or Rosch-Uchida access set
Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Portal Vein Access with Ring or Rosch-Uchida set

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Procedural Success
Time Frame: Index Procedure
Creation of the parenchymal tract between the hepatic vein and an intrahepatic branch of the portal vein confirmed by portogram (CO2/contrast).
Index Procedure
Composite of Major Complications
Time Frame: Through 30 days post-TIPS procedure
Major complications associated with the procedure or study device and defined as complications resulting in an unplanned increase in the level of care, prolonged hospitalization, permanent adverse sequelae, or death.
Through 30 days post-TIPS procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Technical Success
Time Frame: Index Procedure
Creation of a shunt (stent bridging) between the portal and systemic veins.
Index Procedure
Number of Needle Passes
Time Frame: Index Procedure
Count of needle throws between the hepatic and portal vein to create the parenchymal tract.
Index Procedure
Procedure Duration
Time Frame: Index Procedure
Interval (in minutes) from first jugular access for TIPS creation to removal of catheters from the patient.
Index Procedure
Fluoroscopy Time
Time Frame: Index Procedure
Measured in minutes
Index Procedure
Device-Related Complications
Time Frame: Through 30 days post-TIPS procedure
Incidence of complications related to the device as judged by the Investigator
Through 30 days post-TIPS procedure
Portal Vein Access (PVA) time
Time Frame: Index Procedure
Time (in minutes) from the first forward motion of the needle to confirmation of portal vein access via portogram.
Index Procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Venkatesh P. Krishnasamy, MD, New York Presbyterian - Columbia University Medical Center
  • Study Director: Danyel C Carr, MS, Argon Medical Devices

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 13, 2023

Primary Completion (Actual)

October 16, 2023

Study Completion (Actual)

November 19, 2023

Study Registration Dates

First Submitted

March 1, 2023

First Submitted That Met QC Criteria

March 1, 2023

First Posted (Actual)

March 13, 2023

Study Record Updates

Last Update Posted (Actual)

March 8, 2024

Last Update Submitted That Met QC Criteria

March 7, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Diseases

Clinical Trials on Scorpion Portal Vein Access Kit

3
Subscribe